A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
about
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisRecombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patientsEffect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis.Association of pre-transplant erythropoiesis-stimulating agent responsiveness with post-transplant outcomesMortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.Erythropoietin action in stress response, tissue maintenance and metabolism.Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patientsThe effects of erythropoietin dose titration during high-fat diet-induced obesity.A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction.The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION.Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome.Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.Anemia and iron deficiency in heart failure.Therapy of anemia: is it only a number to reach or are there other variables to control?Managing anaemia of chronic kidney disease.Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).A pilot study of chronic, low-dose epoetin-{beta} following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure.Obesity may be erythropoietin dose-saving in hemodialysis patients.
P2860
Q24187413-2CD2A7D5-ACFD-4A33-B2F1-022EF37BD9A5Q24246372-BBD9EF85-1CC7-4BCF-B0B0-7F063A0B1B23Q30241186-1FB5349C-468E-4EFA-946D-1D88FB3DE1BFQ30417992-D508C8D4-9854-44BC-9D97-23D75876AC71Q30422508-BA50E698-7EF7-4261-96EC-2FCE765A778EQ33907747-38CFF07D-F254-4281-9C18-8F6B9D451B45Q34555348-18CC535D-93E0-4232-AA92-D1A53C5A2862Q34897067-C8A53AB7-D941-44E3-842D-45C5BE48AAFBQ35633171-1E48F37D-EB24-444D-8509-448260EADC45Q35801832-C0E310C0-F9F7-4082-8FB5-78A31A2D3E1BQ36039649-E6600835-9618-49E8-9258-D79CE6BF0DB3Q36128396-F06B7625-D566-47B5-B329-E0E1EB8E3D22Q36629130-DAAB8DBD-60AF-44E7-B4B0-30159D7D3B74Q36925390-29AFC328-C503-4A99-90E8-61BE13AC94EFQ37257340-45F5153B-6CF7-41F8-8BE6-86B3E5EAE176Q37765902-11376E77-A266-46CD-ABDE-E4E90A4F93DFQ37791923-31150FD3-549E-4592-BC2E-90A818161573Q37883005-321DE791-DEEA-4E18-8164-6301F44C1AECQ38039849-C3F82E0F-C506-411D-B1A3-CE612233B4FFQ38111881-05ED1E18-1E3D-4C93-8C01-063834123759Q39818102-FA33EA18-C863-4A3E-BB51-CFECD412C9C6Q43426045-C9BAD855-34C8-49EB-A3A8-40C3B825B5CEQ43608007-1893A363-E8FE-4ABE-9D72-5437A2B43882Q44963037-04050849-45E3-4FEB-B721-CC2C3C591AB4Q47111895-57829192-43D0-4814-9EB6-E753E114BE8AQ50442683-584915B1-A6E0-49CD-A7FC-D8D276B15019Q51577468-86C62AC3-0B59-40A2-A6AD-80FAEAEC01C0Q55416565-7426B877-B96A-44F7-A959-25D4D89A9FFF
P2860
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A secondary analysis of the CH ...... comes during anemia treatment.
@ast
A secondary analysis of the CH ...... comes during anemia treatment.
@en
type
label
A secondary analysis of the CH ...... comes during anemia treatment.
@ast
A secondary analysis of the CH ...... comes during anemia treatment.
@en
prefLabel
A secondary analysis of the CH ...... comes during anemia treatment.
@ast
A secondary analysis of the CH ...... comes during anemia treatment.
@en
P2093
P2860
P356
P1433
P1476
A secondary analysis of the CH ...... comes during anemia treatment.
@en
P2093
Adrian Hernandez
Ajay K Singh
Donal Reddan
G Michael Felker
Huiman X Barnhart
Jula K Inrig
Lynda A Szczech
Shelly Sapp
Uptal D Patel
P2860
P2888
P304
P356
10.1038/KI.2009.415
P407
P577
2009-11-04T00:00:00Z
P5875
P6179
1002499447